Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Xbrane Biopharma AB ( (SE:XBRANE) ) just unveiled an update.
Xbrane Biopharma AB has published a disclosure document for the admission of newly issued shares to trading on Nasdaq Stockholm. This follows a directed share issue approved by the company’s board and an extraordinary general meeting, involving over a billion new shares. Certain investments in the directed issue may require review by the Swedish Inspectorate for Strategic Products, with trading expected in August 2025. Pareto Securities and Baker & McKenzie Advokatbyrå KB are advising on the process.
More about Xbrane Biopharma AB
Xbrane Biopharma AB is a company that develops biological drugs using a patented platform technology aimed at reducing production costs. The company has a portfolio of biosimilar candidates targeting significant market potential, with its lead candidate Ximluci® having received market authorization in Europe. Xbrane is headquartered in Solna, Sweden, and is listed on Nasdaq Stockholm.
Average Trading Volume: 15,951,271
Current Market Cap: SEK357.3M
See more data about XBRANE stock on TipRanks’ Stock Analysis page.